New Phase II data indicate regimen of Truxima® (biosimilar rituximab), lenalidomide and acalabrutinib (R2A) may be well tolerated and effective in relapsed/refractory aggressive B-cell lymphoma

Press/Media: Press / Media

Period2020 Jun 14 → 2020 Jun 17

Media coverage

9

Media coverage